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Although humans vary in their response to chemicals, comprehensive measures of susceptibility
have generally not been incorporated into human risk assessment. The U.S. EPA dose-response-
based risk assessments for cancer and the RfD/RfC (reference dose-reference concentration)
approach for noncancer risk assessments are assumed to protect vulnerable human subgroups.
However, these approaches generally rely on default assumptions and do not consider the specific
biological basis for potential susceptibility to a given toxicant. In an effort to focus more explicitly on
this issue, this article addresses biological factors that may affect human variability and susceptibility
to trichloroethylene (TCE), a widely used halogenated industrial solvent. In response to Executive
Order 13045, which requires federal agencies to make protection of children a high priority in
implementing their policies and to take special risks to children into account when developing
standards, this article examines factors that may affect risk of exposure to TCE in children. The
influence of genetics, sex, altered health state, coexposure to alcohol, and enzyme induction on
TCE toxicity are also examined. Key words: children, gender differences, human variability,
susceptibility, trichloroethylene. - Environ Health Perspect 108(suppi 2):201-214 (2000).
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Throughout human history it has been
apparent that only some individuals in a
given population become sick or die after
exposure to a common environmental hazard.
To what extent can we make predictions con-
cerning the effects ofenvironmental agents
on individuals or groups? Determining the
risk of an individual from a specific agent
requires studying the net influence ofa large
set ofvariables on the known effects ofthat
agent. Some ofthese variables may enhance
susceptibility, while others maydiminish it.
Risk assessment has been an important
environmental regulatory decision-making
tool in the United States and Canada since
the 1980s. It is defined as a formalized
process for estimating the magnitude, likeli-
hood, and uncertainty ofenvironmentally
induced health effects (1-3). While the U.S.
Congress has tried to protect susceptible
groups and workers since the 1970s through
legislation [e.g., Clean Air Act (4)], both
research and risk assessment on potential tox-
ins have lagged (5). Historically, U.S. govern-
ment agencies have focused on the maximally
exposed individual in risk assessment. For
example, the health ofindividual workers in
an occupational setting is protected by setting
standards that restrict exposure beyond a per-
missible limit ofa substance (6).
Although humans vary in their response
to a given toxicant, measures ofsusceptibility
have not been incorporated into human risk
assessment methods (5). Since limited base-
line information is available on exposure and
health outcomes in humans, most human
health risk assessment is based on experimen-
tal toxicity studies of homogenous animal
populations; however, these usually do not
evaluate differences in sensitivity, age, or
gender, particularly in human populations.
While the U.S. Environmental Protection
Agency (U.S. EPA) dose-response-based risk
estimates are assumed to protect vulnerable
human subgroups (7), the biological basis of
susceptibility remains poorly understood. In
addition, broadly based exposure baselines
and data on potentially susceptible groups,
such as children or the elderly, are lacking.
The U.S. EPA Guidelines for Risk Charac-
terization (8) have emphasized the need to
identify, characterize, and include susceptible
populations in risk estimation and risk man-
agement processes (9).
This article focuses on human variability
and susceptibility in response to trichloro-
ethylene (TCE) exposure. TCE and other
halogenated hydrocarbons are widely used
industrial solvents, and production ofTCE
increased from approximately 260,000 pounds
in 1982 to 320 million pounds in 1991.
Heavy use ofTCE has resulted in widespread
soil and groundwater contaminants in the
United States; TCE is present in as many as
60% ofthe hazardous waste sites on the U.S.
EPA National Priority List. The major envi-
ronmental releases come from the air emissions
of metal degreasing plants. Thus, TCE has
been the subject ofmuch toxicity testing and
research, and an extensive database has been
compiled (10-13).
In an effort to address factors that affect
human variability and susceptibility, this arti-
cle examines the risks of TCE exposure to
children. Executive Order 13045 requires
federal agencies to make protection ofchil-
dren a high priority in implementing their
policies and to take special risks to children
into account when developing standards. The
order follows the recommendations of the
1993 National Research Council (NRC)
report Pesticides in the Diets ofInfants and
Children (14), which suggested children are
at disproportionate risk from environmental
health threats because they receive greater
exposures per unit ofbody weight, and their
developing systems are immature.
The influence ofgenetics, altered state of
health, and the effect ofenzyme induction on
TCE toxicity are also examined in this article.
Ethanol and TCE interactions are examined
in detail because of the availability of data.
However, the studies on ethanol exposure
and TCE interaction serve as an example of
the potential toxic consequences ofenzyme
induction and exposure to mixtures.
Health Effects ofTCE Exposure
in Humans
Metabolism ofTCE
The metabolism ofTCE is described exten-
sively in another article in this issue (15).
Briefly, TCE is rapidly absorbed following
acute exposure and distributes throughout the
body, preferentially to the fat. TCE under-
goes metabolic activation primarily in the
liver but also in the kidneys and lungs
(Figure 1). The rate-limiting step in the
metabolism of TCE is the P450-mediated
oxidation to chloral hydrate (CH). CH is
rapidly hydrolyzed to trichloracetic acid
(TCA) and free trichloroethanol (TCOH) via
aldehyde and alcohol dehydrogenase (ADH),
respectively. Free TCOH undergoes glu-
curonidation and is excreted in the urine or is
converted back to TCA through CH. TCOH
also undergoes enterohepatic recirculation.
That is, following excretion ofTCOH from
the liver into the bile and then the small
intestines, it is reabsorbed into the intestinal
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Figure 1. Oxidative and conjugative pathways forthe biotransformation ofTCE.
circulation and passes back through the liver.
TCA is metabolized to dichloracetic acid
(DCA) or is excreted in the urine. TCA,
TCOH, and DCA are thought to contribute
to the toxicity ofTCE.
TCE also undergoes metabolism through
glutathione conjugation in the liver to form
dichlorovinyl glutathione (DCVG) (15).
DCVG in turn is metabolized to the cysteine
conjugate in the kidney (DCVC), which is
metabolically activated to a thioacetylating
agent byP-lyase ordetoxified byN-acetyltrans-
ferase (NAT), which isexcreted in the urine.
Acute Effects
Acute exposure to TCE results primarily in
central nervous system (CNS) effects.
Neurotoxic effects, such as dizziness,
headache, sleepiness, nausea, confusion,
blurred vision, andweakness occur at concen-
trations ofapproximately 100 ppm; anesthe-
sia occurs at 2,000 ppm (10,12). Death has
occurred at very high concentrations (10,000
ppm) and was associated with cardiac
arrhythmiaand massive liverdamage (12).
Reproductive/Developmental Effects
Studies on the various reproductive and
developmental effects ofTCE have yielded
conflicting results. One study found an
increase in miscarriage among nurses exposed
to TCE and other chemicals in the work-
place, although no specific association with
TCE was found. Another study found no
increase in malformations in the children of
2,000 fathers and mothers exposed to TCE
via inhalation (12). An association, but no
direct cause-and-effect relationship, was
found between elevated levels ofchlorinated
hydrocarbons, including TCE, and
chromium in drinking water and congenital
heart disease in children whose parents were
exposed to this contaminated drinking water
(16,17); follow-up studies in rats showed that
TCE was a cardiac teratogen, but not a gen-
eral teratogen during fetal organ development
(18). An association between TCE exposure
and cardiac anomalies and eye malformations
has been found (18-20). Other studies, how-
ever, found no adverse reproductive effects in
humans exposed to TCE in drinking water
(12,21). An increase in abnormal sperm mor-
phology in mice exposed to TCE by inhala-
tion has also been found (12,21).
CancerRisk
Long-term exposure to TCE can result in
hepatotoxicity, nephrotoxicity, and neurotox-
icity, as reviewed by Bull (22), Lash (23), and
Barton (20), respectively. Several studies in
humans have investigated the relationship
between TCE exposure and cancer. The U.S.
EPAhas for a numberofyears regulated TCE
on the basis ofcarcinogenicity, although its
classification has not been resolved between
group B2 (sufficient evidence in animals) and
C (limited evidence) (24-26). Two large
bodies in the past fewyears have reviewed the
epidemiologic evidence on TCE. The
American Council of Governmental
Industrial Hygienists (ACGIH) (27), looking
only at the occupational studies, classified
TCE as a compound not suspected as a
human carcinogen, primarily on the basis of
observations from large studies ofdegreasers
at Hill Air Force Base in Utah (28,29).
Several years later, the International Agency
for Research on Cancer (IARC) (30)
reviewed studies from both occupational and
drinking water exposures and noted consis-
tent findings ofliver/biliary tract cancer and
non-Hodgkin's lymphoma in the most infor-
mative studies. Additionally, they noted ele-
vated leukemia risks in the drinking water
studies. However, these populations were
exposed to other solvents in addition to TCE.
These findings led IARC to classify TCE as a
probable carcinogen in humans, or Group
2A, based on limited human and sufficient
animal data (30). It should be noted that the
ACGIH and IARC used different methods to
evaluate the epidemiologic database.
The evidence is increasing for an associa-
tion between human kidney cancer and TCE
exposure; newer studies consistently report
elevated risk of cancer for this site (31-35).
Additionally, nephrotoxicity and kidney dys-
function following TCE exposure have been
reported (36,37). Several studies show ele-
vated risks for breast and cervical cancer
among women occupationally and environ-
mentally exposed to TCE (33,38,39). This
evidence is weaker than that for the afore-
mentioned sites; however, it raises a question
regardingsusceptibility ofwomen.
Although strict site concordance has not
been established in animals and humans for
each specific tumor, increases in lung, liver,
and kidney tumors in animals have been seen.
Inhalation exposure results in the formation of
lung, liver, and kidney tumors; oral gavage
results in increases in liver and kidney tumors
(22,23). Male rats are more susceptible to the
formation ofkidney tumors, whereas mice are
more susceptible to the formation ofliver and
lung tumors. The toxicities resulting from
TCE exposure are likely due to the various
metabolites formed from the oxidative and
conjugative pathways. Qualitatively, the path-
ways ofbiotransformation in humans and ani-
mals are identical, with most metabolites
identified in experimental animals also found
in humans. However, quantitative differences
exist that probably account for the observed
species differences in the formation ofTCE-
induced tumors. Mice and rats metabolize
TCE more efficiently than humans. For exam-
ple, the maximum rate ofthe in vitro metabo-
lism ofTCE in humans is one-third that in the
rat and one-fourth that in the mouse (40).
While the tissue-specific tumors identified
in rodents are due to metabolites rather than
TCE, the metabolite responsible for each
tissue-specific response is likely different.
Animal studies suggest that the formation of
liver tumors is mediated through TCA and
possibly DCA, and species differences are
probably due to differences in the formation
ofTCA (22). Mice are more prone to the for-
mation ofliver tumors and metabolize TCE
more rapidlythan rats orhumans.
As reviewed by Lash (23), the formation
ofkidney tumors in rats is likely mediated by
the reactive thiol formed from the 3-lyase
metabolism of DCVC. DCVC has been
shown to be highly nephrotoxic and muta-
genic in the Ames test (41). The kidney
tumors formed following TCE exposure are
very rare and a single mode ofaction has not
been identified, but studies in animals indi-
cate that mutagenicity and cytotoxicity from
DCVC are involved (23).
The relevance ofthe formation ofkidney
tumors in rats to humans has not been estab-
lished. A recent study reported blood levels of
DCVG, a precursor ofDCVC, in humans
exposed to occupationally relevant concentra-
tions ofTCE (42). Sex-dependent differences
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were also found; peak blood levels in men
were 2-fold higher than in women and were
reached sooner than in females. Since male
rats are more susceptible to the nephrotoxic
and nephrocarcinogenic effects ofTCE and
also have a higher rate ofglutathione (GSH)
conjugation in the liver and kidney, these
findings suggest that men may be at a greater
risk than women ofdeveloping nephrotoxic-
ity from TCE exposure.
The mechanism for the increased risk of
lung tumors in mice is different from the liver
or kidney and is thought to be mediated
through the formation and accumulation of
CH in the Clara cells (43). These cells lack
the capacity to metabolize CH to TCOH,
and the subsequent accumulation ofCH leads
to marked vacuolization ofthe cells. The rele-
vance to humans has not clearly been estab-
lished because ofdifferences in morphology
and metabolism in thelungs.
Analysis ofVariability
and Susceptibility
There has been much debate about whether
environmentally related disease is attributable
more to toxicant exposure or to inherent fac-
tors that affect a person's response to toxi-
cants. Historically, many risk analyses have
focused on variations in responses following
different levels ofexposure (e.g., occupational
versus non-occupational exposure). However,
the risk ofdeveloping an environmentally
related illness may also be influenced by a
person's genetic background, age, gender,
nutritional status, behavior (e.g., exercise,
alcohol, and smoking), past and current
exposure patterns, and interactions between
these factors and between genes.
It is important to note that susceptibility
seldom remains constant. A person's suscepti-
bility to environmental hazards mayvary con-
siderablyduringhis orherlifetime as he orshe
grows and develops from infancy to adult-
hood, changes jobs, adopts habits that affect
overall health, suffers from intermittent ill-
ness, and develops chronic diseases in old age.
Factors include fundamental physiological
variables such as the route ofexposure, the
portal ofentry, anduptake route; for example,
significant differences in physiology are found
between children and adults. Fundamental
variables may in turn be affected by constitu-
tive factors, such as a person's genetic back-
ground (variations in metabolic proteins), sex
(reproductive organs, endocrine systems), age
(stage oflife), and ethnicity (this combines
both genetic and acquired factors such as diet,
cultural practices). Acquired factors such as
health status or diseases (e.g., diabetes, obe-
sity), behavioral factors (e.g., diet, exercise,
stress), and other exposures (e.g., alcohol con-
sumption, exposure to other hazards) also
affectfundatmental physiologicalvariables.
Fundamental PhysiologicalVariables
Genetics ofbiotransformation reactions.
Overview. Given equal exposure to a toxin,
humans vary in their internal processing
depending on genetic background, acquired
characteristics, and other past or ongoing
exposures (44). Inherited mutations that
affect all cells in a person (germline muta-
tions) differ from those that arise in a single
cell and affect only the clonal descendants of
that cell (somatic mutations) (45). Diseases
in the first category tend to be rare and result
from dominant single genes (e.g., Li-
Fraumeni syndrome, familial, bilateral
retinoblastoma, defective DNA repair and
proofreading), and disease is usually indepen-
dent ofenvironmental exposure (44).
On the otherhand, susceptibility genes are
defined as common polymorphic genes that
are found in over 1% ofthe population. They
usually but not exclusively consist ofgenes
involved in metabolic and repair function, or
regulators ofsuch genes, that affect activation
or detoxification of environmental agents
(46-49). In contrast to the rare germline
mutation diseases, specific environmental
exposures are required to induce diseases asso-
ciated with susceptibility genes. While suscep-
tibility genes confer only a modest increase in
risk to persons carrying them, larger numbers
ofpeople are affected, and these genes there-
fore pose a greater public health threat than
the rare, single-gene diseases (43). Unlike dis-
eases resulting from rare germline mutations,
those attributed to susceptibility genes do not
show strict familial aggregation. Indeed, the
same mutation may be found in a variety of
sporadic, nonhereditary diseases.
Historically, most observational studies of
polymorphic metabolic genes have focused on
cancer, particularly tobacco-linked lung
cancer. Identifying specific metabolic gene
polymorphisms in individuals may become a
powerful tool in the future for identifying
those at-risk persons and in targeting disease
prevention. However, at presentwe are unable
to predict environmental diseases based solely
on single metabolic gene mutations. The role
ofeach metabolic gene is complex, and may
be modulated bygene-gene interactions, envi-
ronmental exposure, health, nutritional status,
and other factors. Indeed, a trait that provides
protection against a disease resultingfrom one
compound may increase the risk of disease
from another (6).
There is considerable lack ofdata regard-
ing genetic polymorphisms as they relate to
TCE metabolism and toxicity. Most data on
TCE toxicity have been obtained from studies
using inbred animal strains. These studies are
usually conducted on homogenous rodent
strains maintained on identical diets and liv-
ing conditions, while humans are more
heterogeneous and vary widely in their
behavior and diet. As a further complication,
TCE is metabolizeddifferentlybetween differ-
ent rodent species. Since rodent toxicity data
are extrapolated as a basis for evaluating
human toxicity and form the basis for human
health risk assessment, a better understanding
ofthe metabolic differences between species is
needed. In addition, furtherstudies need to be
conducted on genetic polymorphisms in TCE
metabolism in order to provide a complete
health assessment ofsusceptible populations.
The metabolism ofxenobiotics includes
various dasses ofreactions, such as hydrolysis,
reduction, and oxidation, which result in the
formation ofcompounds that areslightly more
hydrophiic. Examples ofenzymes involved in
these types ofreactions include cytochrome
P450s (CYP), ADH, and aldehyde dehydroge-
nase (ALDH). Additional biotransformation
reactions include glucuronidation, sulfation,
acetylation, methylation, and glutathione con-
jugation, which typically lead to a significant
increase in the hydrophilicity of the com-
pound, whichprovides forrapid urinary excre-
tion. Each reaction as it pertains to TCE
biotransformation will be discussed in further
detail. Much TCE toxicity may result from its
metabolites, and analyzing variations in TCE
metabolism is important in understanding
variable toxicityofthiscompound.
Metabolism bycytochrome P450. One of
the major families ofenzymes responsible for
the oxidation ofxenobiotics is CYP. This fam-
ily ofenzymes contains many genetic variants
that showdifferent levels ofmetabolic activity;
up to a 10-fold difference in CYP activity has
been seen in humans (48,50). Wide interindi-
vidual variation is found in the CYP1A2,
CYP2A, CYP2C, and CYP3 gene subfamilies
(51), and associations between altered geno-
types in CYPlAl, CYP2D6, and CYP2E1
and tobacco smoke-induced lung cancer have
been made (50).
In rats, several CYP450 enzymes meta-
bolize TCE, including the CYP1A, 2B, 2C,
and 2E subgroups (52,53); however, TCE
metabolism is most strongly dependent on
CYP2E1 activity. CYP2E1 is well conserved
in mammals, and also metabolizes ethanol and
awide range ofother volatile organic solvents.
At present, it is not clear what CYP450
enzymes other than CYP2E1 are involved in
TCE metabolism in humans (15). CYP2E1
metabolizes awide range ofsubstances includ-
ing nitrosamines and chlorinated solvents
(54). As reviewed by Lieber (55), CYP2E1 is
involved in the metabolism ofover 80 exoge-
nous substances. It is primarily expressed in
liver but also in brain, kidney, andlung.
Interindividual variability in humans.
CYP2E1 activity in vitro has been studied in
liver microsomes from several human popula-
tions. Peter et al. (56) found up to 10-fold
range in activity in 14 subjects, while
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Stephens et al. (57) andYoo et al. (58) found
a 50-fold variation among subjects.
Pronounced differences have also been
observed among Swedish, Japanese, and
Chinese subjects (54). According to Lieber
(55), a 6- to 20-fold variability ofCYP2E1
protein or activity has been observed in
humans and cannot be attributed to liver
disease, cancer, alcohol, orsmoking.
CYP2El-mediated TCE metabolism in
humans. In humans, CYP2E1 plays a crucial
part inTCE metabolism and is responsible for
over 60% ofTCE clearance (40). An 8-fold
variation in the in vitro CYP2E1-mediated
metabolism ofTCE was seen in 23 human
liver samples (40). There were no significant
sex-dependent differences in overall TCE
metabolism or CYP2E1 activity, but the affin-
ity (K,) was lower in females than in males.
Greater variability was seen in women and
mayhave been due to thesmall sample size.
Although a better understanding of
CYP2E1 variation will allow persons more
susceptible to TCE toxicity to be more easily
identified (54), CYP2E1 activity alone is not
asufficient indicatorofrisk. Genetic variation
and diet both contribute to thewide variation
in CYP2E1 activity, and the balance between
activation ofTCE to toxic metabolites and
their subsequent detoxification determines
the risk ofexposed persons (59). In addition,
acquired factors that increase CYP2E1 activ-
ity (e.g., alcohol exposure) may also increase
susceptibility to TCE-induced toxicity.
Interspecies variability in TCE metabo-
lism. Several species-dependent differences in
the metabolism ofTCE have been found.
Lipscomb et al. (40) directly compared the
metabolism ofTCE in hepatic microsomes of
mice, rats, and humans at occupationally rele-
vant TCE concentrations. P450-dependent
TCE metabolism was highest in mice, lower in
rats, and substantially lower in humans. The
maximal rate ofTCE metabolism in humans
was one-fourth and one-third ofthat in the
mouse and rat, respectively. Clearance values
(Vn,,j,/Km) also exhibited species dependence;
human microsomes were the least efficient at
metabolizingTCE.
Species-dependent differences also exist
in the metabolism of CH, which occurs in
both the liver and blood. For example,
metabolism of CH to TCOH was much
lower in human blood than in mice or rats,
while TCA formation was significantly
higher in humans and mice than in rats (60).
Human liver showed only about a 60% con-
version of CH to TCA and TCOH com-
pared to rodent samples. In all species, the
Km for TCOH formation in liver was at least
10-fold lower than TCA formation. Km val-
ues for both TCOH and TCAwere higher in
humans than in rats and mice, and clearance
ofTCOH was higher than TCA (60).
Nakajima et al. (52) examined differences
between rat and mouse liver microsomes in
the metabolism of benzene, toluene, and
TCE by P450 and concluded the species dif-
ferences observed during P450 induction
were more relevant to TCE toxicity than the
differences in basal enzyme levels. That is, the
effect ofdifferences in CYP2E1 activity on
the toxicity ofTCE became more apparent
following CYP2E1 induction. Different
isozyme distributions and substrate affinities
were observed, with mice showing greater
TCE metabolism than rats (52).
Molecular markers andethnicdifferences.
Variability in the regulation of CYP2E1
expression may play a role in susceptibility.
Restriction fragment length polymorphisms
(RFLP) have been identified in the CYP2E1
gene using a variety of restriction enzymes
(58). Variations in allelic distribution were
observed when different ethnic groups, such
as European Americans, African Americans,
and Taiwanese were compared, and particular
alleles were positively correlated to protection
from lung cancer (61); however, this study
did not control for gender, age, or smoking.
A rare allelic form ofCYP2E1, c2, may be
correlated to an increased risk for lung cancer
(62). There was an association between
increased incidence of a particular (DraI)
allelic distribution in Japanese lung patients
(62). This allele was less prevalent in Finnish
and Swedish patients, and the correlation
between the DraI marker and lung cancer
was not found in a Swedish study (63). Kato
et al. (64) also found no correlation between
RsaI markers and lung cancer risk in a study
oflargely Caucasian lung cancer patients.
Mutations in regions outside ofthe CYP2E1
gene may also play a role. For example, a sig-
nificant association was found for a RsaI poly-
morphism in the gene promoter region of
CYP2E1 in Swedish lung cancer patients
(64); however, no significant correlation was
found in Finnish and Japanese patients with
lung cancer (65,66). In another example, a
significantly higher distribution of the c2
mutation was found upstream ofCYP2E1 in
controls for lung cancer; this region contains
a putative binding site for transcription factor
HNF-4. CYP2E1 may be less efficiently
expressed among carriers ofthe c2 mutation,
making them less susceptible to xenobiotic
bioactivation (64). Examination ofCYP2E1
variants in nasopharyngeal cancer cases and
controls showed an RFLP distribution similar
to theJapanese population but higher than in
the Finnish or Swedish population (67). A 5-
to 7.7-fold increase in cancer risk was found
in subjects homozygous for these CYP2E1
variants.
Although molecular markers clearly indi-
cate differences in metabolic genes in different
groups, at present none ofthese sites can be
used as markers for predicting increased
disease risk (10). In the absence ofdatadirectly
relating polymorphisms to enzymatic activity,
this information remainsoflimited use.
Alcohol dehydrogenase. ADH is a mul-
tienzyme family found in the cytosol, mito-
chondria, and endoplasmic reticulum of
many tissues. Six human ADH genes have
been characterized, and polymorphisms of
several ADH genes have been identified
(68-73). The enzymes have been divided
into three classes according to isozyme com-
position and kinetic properties. Class I ADH
consists of three nonallelic loci, ADH1,
ADH2, and ADH3, which are involved in
the synthesis ofthree types ofsubunits, a, P,I
y, respectively (72). Genetic variants of
ADH2 andADH3 exist and encode for high-
activity ADH (68). For example, the fre-
quency of these variants is higher among
Asians (68,69). Atypical ADH contains a
variant 0 subunit (32) instead of the usual
p1, and is found more frequently among
Asians than Caucasians (70). Class I ADH
exhibits high catalytic activity toward short-
chain aliphatic alcohols, including ethanol, as
well as biologically active amines (72). Class
II and Class III ADH exhibit catalytic activity
toward longer chain alcohols (71). Class IV
ADH consists ofthe enzyme that is primarily
responsible for gastric metabolism ofethanol,
a-ADH (74). ADH is involved in the metab-
olism ofCH to TCOH. Thus, ethnic vari-
ability in ADH metabolism may result in
variations in the formation ofTCOH, which
can alter the hypnotic/CNS effects following
TCE exposure.
Aldehyde dehydrogenase. ALDH is a
group ofenzymes that convert aldehydes to
corresponding acids. ALDH is inducible by
certain medications, such as barbiturates
(75). Approximately 50% ofEastAsians have
an inactive ALDH enzyme (mitochondrial
ALDH2), but active ALDH is present in vir-
tually all Caucasian, African-American, and
North and SouthAmerican populations stud-
ied (70). Persons lacking this enzyme develop
a flushing reaction following ethanol con-
sumption due to the buildup ofacetaldehyde
(68).
ALDH is involved in the metabolism of
CH to TCA. A decrease in the formation of
TCA, which could potentially occur in per-
sons lacking this enzyme, could protect
against the toxic effects ofTCA. However, an
increase in flux through the conjugative path-
way can occur secondary to a decrease in the
formation ofTCA from CH. Thus, genetic
variations in either enzyme will likely have an
effect on the metabolism and toxicityofTCE.
However, no studies have been conducted to
examine this.
Glutathione conjugation. Glutathione S-
transferase (GST) conjugates'TCE with
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glutathione to form DCVG; this is further
metabolized in the kidney to the cysteine
derivative DCVC, which is activated by 3-
lyase or detoxified by NAT. While conjuga-
tion products are generally less toxic than the
parent compound, some TCE metabolites,
such as the nephrotoxin DCVC, are more
potent (76). While variations in conjugative
reactions of TCE biotransformation in
humans are not well documented, below are
summarized the known variants in GST.
Defective GST genes are associated with
an increased risk oflung and bladder cancer
(30). About 50% ofCaucasians are homozy-
gous for the null allele of GSTMI (51) and
may be at greater risk for certain cancers. In
addition, different GST subfamilies show
marked tissue specificity and developmental
regulation. For example, placenta contains
only GST n activity, and 50% offetal liver
GST activity is from the n form, which is not
expressed in adult liver.
The GST family encodes multifunctional
enzymes that catalyze several reactions
between GST and electrophilic and
hydrophobic compounds (51). The four
multigene classes ofGST subunits are a, p, x,
and 0. Approximately 60-70% ofhumans are
conjugators who can conduct GSH-depen-
dent detoxification ofmonohalomethanes,
while nonconjugators cannot (51).
GST,u. GSTp1 detoxifies a number of
reactive electrophilic substances. About
50-60% ofCaucasians carry the GSTp1 null
phenotype (51). This is consistently associ-
ated with a higher risk for lung and bladder
cancer (77-79), and possibly skin (80) and
colon cancer (81,82). Indeed, 25% of all
bladder cancers may be correlated to smokers
carrying the GST null phenotype (77). Gene
and environmental interactions may also be
significant; nonsmokers carrying the GSTpl
null phenotype do not show elevated bladder
cancer risk, but risk increases 2- and 6-fold
with smoking (83).
GSTO. GSTO enzymes conjugate anumber
ofchlorinated low-molecular-weight com-
pounds, and may be primarily responsible for
conjugation ofTCE (15). The GSTO gene is
present in 60-75% ofhumans, and at least
two classes ofenzymes are found in liver and
in erythrocytes (84). Distribution of the
GSTO1 polymorphism varies among ethnic
groups (84-86), and is associated with an
increase in sister chromatid exchange rates,
particularly with exposure to tobacco smoke or
diepoxybutane (87,88).
GSTp1 and GSTO1 polymorphisms may
be important in renal cell cancer development
following high occupational TCE exposure.
Bruning et al. (89) found unequal distribu-
tions ofthe GSTji1 and GSTO1 genotypes
between renal cell cancer patients and controls,
suggesting that these polymorphisms indicate
predisposition toward this disease. Enzyme
polymorphisms were found in renal cell cancer
patients who had high occupational TCE
exposure, resulting in irreversible tubular dam-
age. The authors concluded that glutathione-
dependent formation of nephrotoxic
metabolites is responsible for induction of
renal cell carcinoma by TCE, and that this
genetic polymorphism may indicate a predis-
position for TCE-induced renal cell cancer. In
addition, persons with polymorphisms in both
the GST1i and GSTO genes show a synergistic
riskforlungcancer (90).
Ethnicity. Different ethnic groups vary in
their distribution ofgenotypes, and extrapola-
tion ofhealth outcomes among the groups is
verydifficult (51). For example, genetic poly-
morphisms in CYP450 were found in
debrisoquin and (S)-mephenytoin hydroxyla-
tion (catalyzed by CYP2D6 and CYP2CMP
respectively) when Japanese and Caucasian
populations were compared. In a separate
study, Shimada et al. (91) examined the dis-
tribution and activity of P450 isoforms in
liver microsomes from 30 Japanese and 30
Caucasian patients. No significant gender-
related differences were seen in either popula-
tion, and the proportion of CYP2E1 in
CYP450 was not affected by gender or age.
While total CYP450 content and activity
were higher in Caucasians, the relative
CYP450 isoform levels were similar except for
CYP2A6 and CYP2B6, which were higher in
Caucasians. Differences in CYP4501A2, 2A6,
2D6, 2E1, and 3A4 activity levels were
observed, but no difference in CYP2CMP
was seen.
Biologically plausible mechanisms to link
specific genotypes to specific outcomes are
still lacking for most environmental diseases;
for example, many RFLP polymorphisms in
Class I genes are the result of mutations in
introns or other silent areas of the human
genome (51). RFLP analysis is therefore of
limited use in predicting an individual's sus-
ceptibility at this time but may provide some
insight into the mechanisms ofsusceptibility
among different groups. DNA sequence
analysis, either by direct sequencing-or by
hybridization-based analysis ofpolymorphic
sites via DNA chips, is likely to be ofconsid-
erablygreater use in the near future, however.
Sex. Susceptibility differences between
males and females have been studied only for a
few environmental pollutants, most notably
inhaled agents such as cigarette smoke and car-
bon monoxide (92,93). Several epidemiological
studies ofcigarette smoke have shown that, at
the same exposure level, women differ in their
resistance to lung damage compared to men.
Xu et al. (94) report that adverse effects of
smoking on pulmonary function are greater in
women than in men, and other studies indicate
sex differences in lung dysfunction, and in
genetic and biochemical alterations in lung
cancer (95-97).
In addition to differences in the internal
processing ofthese toxins, sex affects many
aspects oflung growth and development as
well as structure and function. There are sex-
related differences in how airborne pollutants
are deposited in the lung and in the pul-
monary response. This may be important
because most TCE exposure comes from
inhalation.
There are limited data on sex-dependent
differences in the toxic response to TCE.
Recent epidemiological studies show an excess
risk of breast and cervical cancer among
women exposed occupationally and environ-
mentallytoTCE (33,38,39). A recent analysis
of the TCE and TCA National Exposure
Registry (NER) revealed significant sex-
dependent differences in reported adverse
health outcomes (39). In this study, a com-
parison between data from the registry and
national norms found significantly greater
increases in diabetes, kidney problems, liver
problems, and urinary tract problems in
women. Although this registry contains self-
reported adverse health outcomes and thus
cannot be used to draw definitive conclusions,
itdoes provide abasis forfurtherstudies.
Recent studies have found significant sex-
dependent differences in the toxicokinetics of
TCE. For example, higher blood concentra-
tions of the glutathione conjugate DCVG
were found in men compared to women fol-
lowing exposure to either 50 or 100 ppm
TCE (42). Peak blood levels in men were 2-
fold higher than in women at 100 ppm and
were obtained sooner (2 and 4 hr in men and
women, respectively). Since male rats are
more susceptible to the nephrotoxic and
nephrocarcinogenic effects ofTCE and also
have a higher rate ofGSH conjugation in the
liver and kidney (98), these findings suggest
that men may be at a greater risk ofdevelop-
ing nephrotoxicity from TCE exposure.
Additional studies have also revealed sex-
dependent differences in the toxicokinetics of
TCE. For example, in vitro studies using
human tissue found that males and females
differed significantly in their affinities to oxi-
dized TCE (40). An uncertainty and variabil-
ity analysis of data obtained from subjects
exposed to 50 and 100 ppm TCE revealed
sex-dependent differences in various simu-
lated pharmacokinetic parameters (99). TCE
also distributes preferentially in fat, and
women have agreater percentage offat. Thus,
these pharmacokinetic differences have the
potential to result in differential susceptibility
between men andwomen exposed to TCE.
Susceptibility ofchildren to TCE. The
majority ofresearch pertaining to environ-
mental health risks in children relates to
asthma, ozone, and environmental tobacco
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smoke. Research pertaining to the effects of
TCE in children has focused primarily on
potential teratogenic effects. Limited studies
suggest a link between exposure to TCE and
cardiac malformations, but conflicting results
have been found (100,101). The Agency for
Toxic Substance and Disease Registry
(ATSDR) reported no increase in malforma-
tions in children whose parents were exposed
to TCE via inhalation (12). However, Swan
et al. (16) and Goldberg et al. (17) found a
link between the elevated levels ofhydrocar-
bons, including TCE, in the drinking water
and cardiac malformations. These results
were consistent with studies in rats that found
an increase in cardiac malformations (100).
Drinking water studies also found an increase
in CNS defects, neural tube defects, and oral
cleft defects (101). Although these effects
were attributed to TCE, there were other sol-
vents present in the drinking water, making a
distinct correlation withTCE difficult.
Attention is now being focused on the
health effects ofTCE in the child. Recently,
in their comparison between self-reported
health outcomes from persons enlisted in the
TCE and TCA NER and national norms,
Burg and Gist (39) found an increase in
reports of hearing and speech impairment
children 0-9 years ofage, with girls reporting
higher rates. In addition, an increase in the
rate of urinary tract disorders was also
reported for most age groups, induding chil-
dren. As previously discussed, data obtained
from the registry are useful for identifying
areas offurther research but do not provide
conclusive evidence. However, ATSDR has
recently undertaken studies to examine the
link between TCE exposure and hearing and
speech impairment in children.
The main exposure routes to TCE are
through ingestion and inhalation. In chil-
dren, oral exposures are most often associ-
ated with consumption of water, while
inhalation may occur during use ofwater for
activities such as showering. Exposure can
also occur transdermally. In addition to
potentially higher exposure in children,
developmental differences in absorption, dis-
tribution, metabolism, and excretion can
alter susceptibility in children exposed to
TCE. Specific factors that affect the forma-
tion and excretion of toxic metabolites
deserve consideration, as they may alter toxi-
city. Data on the dosimetry ofTCE in chil-
dren are virtually nonexistent; therefore, the
discussion below focuses on potential differ-
ences in response between adults, children,
and the fetus. It should be noted that poten-
tial differences do not necessarily reflect an
increase in susceptibility among children.
The specific nature ofeach response must be
considered and certain factors may actually
provide a protective role.
Age-dependent effects on absorption.
The absorption ofTCE occurs primarily
through inhalation and through the gastroin-
testinal tract but can also occur transdermally.
Each ofthese processes is different in children
versus adults and may affect the dosimetry of
TCE. Oral absorption ofchemicals in the
neonate can be affected by several factors. For
example, the gastric pH will affect the absorp-
tion ofionized drugs and chemicals. The gas-
tric pH is neutral at birth as a result ofthe
presence ofamniotic fluid in the stomach
(102), decreases to approximately 1-3 within
hours after birth, reaches neutrality at 8 days,
and slowly declines to 2-3 by 3 months
(103). Although there are age-dependent dif-
ferences in gastric pH, nonionized lipophilic
compounds such as TCE readily diffuse
across membranes. Thus, altered gastric pH
will likely not affect the absorption ofTCE.
Prolonged gastric emptying, which is
observed in the neonate (104), and increased
gastric and intestinal motility, which occurs
in young children (105), can potentially
affect the oral absorption ofTCE. TCOH, a
metabolite ofTCE, undergoes glucuronida-
tion and enterohepatic recirculation, which is
affected bya decrease in gastric acid secretion.
Transdermal absorption ofchemicals is
significantly higher in the child than the adult
because ofthe greater surface area relative to
body weight, which is approximately 2.7-fold
greater in children (103,105). In addition, in
the neonate and infant the epidermis and
stratum corneum are thinner, facilitating
much greater dermal absorption (103,105).
Because of its lipophilicity, TCE could be
transdermally absorbed to a greater extent in
children than in adults.
Inhalation also differs between children
and adults because of physiological and
anatomical differences, as reviewed in
Guzelian et al. (106) and Snodgrass (107).
The newborn has approximately 10 million
alveoli; adult levels of 300 million are not
reached until 8 years of age. The alveolar
surface area increases from 3 m2 at birth to
75 m2 in adulthood; as a result, the air-to-
tissue gas exchange increases more than 20-
fold. In addition, although the respiratory
volume is the same in adults and children
(10 mL/kg bodyweight/breath), the number
of breaths per minute is increased in the
infant [40 breaths/minute in the infant ver-
sus 15 breaths per minute in the adult;
(107)]. Thus, the respiratory minute venti-
lation is greater in children [133 vs 2 mL/kg
body weight/m2 lung surface area/min;
(107)]. One ofthe primary routes ofexpo-
sure to TCE is via inhalation, and all of
these factors may alter the dosimetry ofTCE
in the child compared to the adult.
However, no studies have been conducted to
evaluate these factors.
Age-dependent factors in distribution.
Factors such as blood flow, tissue volume,
and protein binding affect the distribution of
chemicals and also vary with age. For exam-
ple, protein binding is decreased in children
primarily as a result ofan increase in the con-
centration of nonesterified fatty acids
(108,109). Plasma albumin is also decreased
in children (108,109). These factors will
likely not affect the distribution ofTCE in
children because TCE does not bind signifi-
cantly to proteins.
However, the distribution ofTCE will
likelybe affected by factors that affect thevol-
ume ofdistribution. Lipid-soluble chemicals
such as TCE should have a smaller volume of
distribution in infants because ofchildren's
larger percentage oftotal body water. Total
body water constitutes as much as 85% of
body weight in preterm and 78% of body
weight in full-term neonates (110,111),
decreasing to 55% by 12 years ofage (112).
Because fat content also varies throughout
development, periods offat reduction may
result in increased dosage to the liver or other
target organs. For example, fat content
increases between 5 and 10 years ofage, fol-
lowed by a decrease in boys at age 17 (111).
In girls there is a rapid increase at puberty;
young females have approximately 2 times
greater percentage body fat than boys, sug-
gesting that females will accumulate TCE to a
greater extent than males. The half-life of
TCE in the fat ofadults is 3.5 hr, whereas in
rapidly and slowly perfused tissue the half-life
is 2-4 min (11). Therefore, TCE can be
released from the fat for several hours, result-
ing in prolonged delivery to various target
organs.
TCE is a centrally acting chemical and
distributes to the brain. Thus, differences in
brain volume and blood flow to the brain can
alter the toxicokinetics ofTCE in children
compared to adults. The brain weight in the
newborn is approximately 33% ofadult val-
ues, whereas the bodyweight ofthe newborn
is 4%. After birth, the brain continues to
develop and is therefore susceptible to insult.
Brain growth is very rapid during the first 2
years and contains 75% ofall cell types byage
2, but further growth is due to myelination of
subcortical white matter, elaboration ofneu-
ronal dendrites and axons, and an increase in
the number ofglial cells. Thus, the newborn's
brain is more lipophilic, which can affect the
distribution ofchemicals such as TCE.
Age-dependent effects on metabolism. In
general, children are believed to metabolize
and clear xenobiotics faster than adults.
However, the metabolism ofxenobiotics in
the infant and child is dependent on the spe-
cific enzyme systems involved for each chemi-
cal. Some enzymes present at birth do not
reach adult activity levels for months or years.
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Others are present in the fetus and reach adult
capacity at birth. It is therefore important to
consider chemical-specific metabolic pathways
when examining the potential risks in chil-
dren, since the ontogenicity differs for each
enzyme system.
CYP2EL. As with adults, one ofthe most
important enzymes to consider in the evalua-
tion oftoxicity from exposure to environmen-
tal chemicals in children is CYP2E1. This
enzyme is responsible for the metabolism of
over 80 exogenous substances, including TCE
(55). Expression ofCYP2E1 in the placenta
or fetus could potentially result in the forma-
tion ofhigh local concentrations ofmetabo-
lites and lead to higher exposures in fetal
tissues than would be expected from maternal
exposure. Depending on the physiochemical
properties, these metabolites may be unable to
exit the placenta and accumulate in the fetal
compartment. Moreover, the possibility for
transplacental induction poses additional
threats.
Recent studies have been conducted to
examine the expression and activity of
CYP2E1 in the human fetus and placenta.
Many ofthese studies were motivated by an
attempt to elucidate a mechanism for the
effects ofethanol on the fetus. In one study,
CYP2E1 was detected in human fetal liver
during the second trimester, at about 16
weeks of gestation (113). The molecular
weight was slightly lower than in adults, but
the enzyme was able to metabolize ethanol at
12 and 27% ofadult capacity. However, at
10 weeks ofgestation, CYP2E1 mRNA levels
were undetectable in embryo liver samples.
CYP2E1 was inducible in human fetal hepa-
tocytes treated with ethanol and clofibrate,
and a 4-fold induction in CYP3A1 was also
found following treatment with rifampicin.
CYP2E1 has also been detected in extrahep-
atic tissues. For example, the expression of
CYP2E1 was detected in human placenta
(114-116). CYP2E1 was also identified in
prenatal human cephalic tissues (117).
Northern blot analyses ofmRNA levels from
tissues obtained between days 54 and 78 of
gestation showed that CYP2E1 levels
increased as a function ofage but were much
lower than hepatic levels.
Despite these findings, conflicting reports
exist regarding the presence ofCYP2E1 in
fetal liver. Vieira et al. (118) found that
CYP2E1 was absent from fetal liver but rose
immediately after birth regardless ofthe gesta-
tional age at birth, which ranged between 25
and 40weeks. This suggested CYP2E1 regula-
tion was directly related to parturition events
rather than temporal maturation itself. The
level ofthe protein and its catalytic activity
steadily increased during the firstyear to reach
adult values in children age 1-10 years. In
addition, the kinetic properties of CYP2E1
were investigated using cloroxazone as a
substrate in both neonatal and adult microso-
mal preparation. The affinity was greater in
newborns compared to adults; Km values
obtainedwere 15.8 and 28.8 pM, respectively.
However, the capacity was similar, with a
Vmax of 0.96 nmol/mg protein/min in the
neonate and 1.0 nmol/mg protein/min in the
adult. These findings are consistent with pre-
vious studies examining the expression of
CYP2E1 in fetal tissues (119). In this study,
CYP2E1 expression was absent in the placenta
either at 10 weeks or 18 weeks ofgestation. In
addition, CYP2E1 expression was not
detected in fetal liver, kidney, lung, and pla-
centa at 18 weeks or in the liver at 6 weeks
ofgestation.
Differences between studies detecting the
presence ofCYP2E1 and those that do not
are due, at least in part, to timing of the
studies. The placenta and fetus are continu-
ally growing and thus expression ofCYP2E1
is likely dependent upon the developmental
stage. While some human studies have shown
the presence ofCYP2E1 in fetal hepatic and
extrahepatic tissues of different gestational
ages, in animals CYP2E1 is present only after
birth. The rat CYP2E1 gene appears to be
transcriptionally activated at birth, only after
which is it detected in rat hepatocytes (120).
The expression ofCYP2E1 in rabbits did not
begin until 2 weeks ofage and reached twice
the adult level between weeks 3-5, the time
ofweaning (121). In kidney, CYP2E1 was
expressed at 1 weekofage.
Clearly, the data indicate that develop-
mental expression and activity ofCYP2E1 in
humans must be explored more fully. This is
particularly important because this enzyme is
responsible for the biotransformation of
many xenobiotics, including metabolically
activated compounds such as TCE. A com-
plete assessment ofthe health effects ofTCE
in the fetus and child requires knowledge of
the metabolism, particularly by CYP2E1, in
this population.
Additional metabolizing enzymes. As with
the CYP450 enzymes, the expression and
activity ofseveral other enzyme systems in
humans vary depending on the developmen-
tal stage. For example, glucuronidation in the
child reaches adult values at 3-6 months
(122). Thus, the fetus and neonate probably
lack adult capacity to form the glucuronide of
TCOH, which can potentially lead to an
increase in the formation ofTCA and DCA.
Since these metabolites are toxic, the fetus
and neonate could potentially be more sus-
ceptible to TCE-related toxicity.
Ofadditional concern to children is the
decrease in ADH activity. ADH activity is
present in fetal liver at the second month of
gestation, but this activity is only 3% ofadult
levels (123). The diminished ADH activity
appears to have an effect on the clearance of
several drugs and chemicals, including CH, a
metabolite ofTCE. For example, the elimina-
tion half-life ofCH was much greater in the
preterm fetus (39.8 hr) than in the neonate
(27.8) or child (9.7, age 1-13 years) (124).
Metabolism in Rodents. Studies in pregnant
and immature rodents can lend insight into
mechanisms ofeffects ofexposure to environ-
mental chemicals and potential toxicity to
humans, particularlywith regard to the contri-
bution ofmetabolic differences. Several studies
have been conducted examining the expression
of metabolic enzymes in the developing
rodent. Hepatic microsomal monooxygenase
activity isverylowduring fetal development in
most mammals but increases rapidly after
birth. Sex-specific regulation ofcertain P450
isozymes occurs during development. For
example, CYP2C1 1 was found at significant
levels in immature (4-week-old) male rats, and
liver levels increased 30-fold in male but not
female rats at puberty (125,126). In addition,
microsomal protein levels were higher in
immature male rats versus females; protein lev-
els increased during development, but at
puberty no sex differences were found. No dif-
ference in net P450 content was seen between
immature male and female rats, but marked
differences were seen at puberty. Pregnancy
decreased the P450 content but not thelevelof
microsomal protein.
Nakajima et al. (52) examined the effects
ofsex, age, and pregnancy on toluene and
TCE metabolism in rat liver. CYP2E1 levels
were higher in immature than in mature rats,
especially at low substrate levels. At puberty,
CYP2E1 levels were higher in females than in
males. In general, TCE metabolism was
higher in immature than in mature rats, espe-
cially at low substrate levels. No sex differ-
ences in metabolism were seen with age or
with varied TCE concentration. However,
pregnancy decreased the metabolism ofboth
toluene and TCE.
Age-dependent effects on excretion.
Several processes involved in the excretion of
chemicals may be affected by age. Polar com-
pounds can be excreted unchanged, whereas
most lipophilic compounds are readily
excreted following metabolism to more polar
forms. Lipophilic chemicals are also elimi-
nated through exhalation. Pulmonary excre-
tion occurs primarily with gases and vapors,
such as TCE. As described above, lung devel-
opment is different in children and mayaffect
howTCE is excreted in breath.
Biliary and fecal excretion are additional
pathways. Many metabolites are excreted
from the liver into the bile by specialized
transport systems similar to those in the
renal tubule, and competition for transport
can occur between ions of like charges.
These chemicals are either excreted in the
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feces or reabsorbed into the blood and
excreted into the urine, a process known as
enterohepatic recirculation (EHR). EHR
occurs primarily with organic ions, such as
glucuronides or cations. In the child, biliary
acid secretion is decreased, which will alter
EHR (127). The glucuronide conjugate,
trichloroethanol glucuronide (TCOG), is
excreted in the bile, undergoes EHR, and
does not get excreted into the feces (15).
Thus, decreased biliary acid secretion in the
child will probably alter EHR ofTCOG and
may alter the toxicity ofTCE.
Elimination of chemicals can also be
affected by factors such as the glomerular fil-
tration rate (GFR). The GFR in newborns is
low but reaches adult levels by 3 months of
age (128). Since many chemicals are elimi-
nated in the urine, including several TCE
metabolites, developmental differences in the
GFRmayaffect overall elimination.
A potential excretory pathway for TCE in
adult women that may be ofparticular con-
cern for infants is lactation. TCE is lipophilic
and is excreted in the breast milk. However,
no studies have been conducted on the
dosimetry of TCE in breast-fed infants.
Recently, a physiologically based pharmacoki-
netic (PBPK) model was developed to
describe the transfer ofvolatile chemicals in
breast milk, including TCE (129). An inter-
mittent acute exposure to 50 ppm ofTCE
was simulated using previously published
physiological and metabolic values for a lac-
tating woman (2-3 months postpartum). The
simulated nursing schedule consisted ofeight
12-min nursing bouts over a 24-hr period.
The predicted amount ofTCE ingested by
the infant over the 24-hr period was 0.496
mg compared to the U.S. EPA Health
Advisory Intake Limits of0.6 mg/day for an
adult consuming 2 Lofwater perday.
While this estimate would suggest that
breast-fed infants are not at increased risk
from exposure to TCE in breast milk, several
factors need to be considered. The output,
that is, the amount ofTCE ingested by the
lactating infant, is compared to drinking
water limits for an adult and may or may not
be appropriate for the child. Moreover, the
model simulated the 2- to 3-month-old
infant not the newborn or older infants. The
model also simulates only parent compound
and does not consider the transfer ofmetabo-
lites. Studies in rats showed that TCA reaches
the suckling pup at 30 and 50% ofmaternal
levels following exposure of the mother to
TCE in the drinking water and through
inhalation, respectively (130). Thus, given
these factors and the small difference between
PBPK model predictions and the U.S. EPA
advisory, conclusions regarding the safety of
exposure to TCE in breast milk need to
be reevaluated.
Clearly there are many factors that have
the potential to alter the dosimetry and toxic-
ity ofTCE in the child. Any one ofthese fac-
tors alone may play a role in susceptibility.
However, in order to provide a scientifically
justifiable assessment ofrisk to children, these
factors need to be considered simultaneously.
The most useful tool for accomplishing this
task would be a PBPK model for TCE in the
growing child. Despite potential limitations,
the development of the PBPK model
described above is a useful step in this process.
Acquired FactorsThatAfifct
PhysiologicalVariables
A number ofacquired factors affect metabolic
gene expression and function, and include
health status, prior and concurrent exposure
to other substances, and behavioral patterns.
Susceptibility to TCE can be altered by these
factors because manyofthem have the poten-
tial to alter toxicity secondary to CYP2E1
induction. Factors that lead to an induction
of CYP2E1 include, but are not limited to,
uncontrolled diabetes, obesity, and prior
exposure to certain solvents (131). CYP2E1
is also induced by certain medications, such
as barbiturates, and by excessive alcohol con-
sumption (55,132). The chronic use ofbarbi-
turates, as often occurs in epileptics, increases
protein and lipid content ofhepatic smooth
endoplasmic reticulum, and also increases the
activity ofglucuronyl transferase and various
CYPP450s, including CYP2E1 (133).
Comprehensive reviews on the mechanism
for CYP2E1 induction in various popula-
tions, and on the physiological and pathologi-
cal role ofCYP2E1, are provided by Raucy et
al. (131) and Lieber (55), respectively.
It is important to consider these popula-
tions in evaluating susceptibility, given the
number of persons who fall into one or
more of these categories. For example, 14
million people in the United States meet the
diagnostic criteria for alcohol abuse or alco-
hol dependence (68). The prevalence of
insulin-dependent diabetes in the United
States is 300,000-500,000, with 30,000
new cases diagnosed each year (134). The
incidence ofdiabetes is affected by sex, race,
and age (134,135).
Very few studies have been conducted on
toxicokinetic interactions between TCE and
these risk factors, with the exception of
ethanol. Although the discussion below will
focus primarily on interactions between
ethanol and TCE, this serves as an example of
potential consequences ofTCE exposure in
persons with induced CYP2E1, as well as the
influence ofexposure to mixtures.
Ethanol Interactions. Concurrent expo-
sure to TCE and ethanol is likely to occur in a
large number of people, and ethanol may
increase susceptibility to the adverse health
effects ofTCE. Alternatively, it can be viewed
that exposure to TCE can aggravate the effects
ofethanol. This interaction may be an impor-
tant health problem because, as discussed
above, both alcohol and TCE exposure are
widespread in the United States. Ethanol and
TCE are centrally acting chemicals and expo-
sure to high levels can cause profound CNS
depression (75,136). Manyenzymes responsi-
ble for TCE metabolism are also involved in
the metabolism ofethanol.
Approximately 75-90% of ethanol is
metabolized through oxidation in the liver,
primarily by ADH, although metabolism can
also occur in other tissues, such as the kidneys,
gastric mucosa, and brain (Figure 2)
(137-139). Ethanol is also metabolized by
CYP2E1 (140). The contribution ofCYP2E1
to the metabolism ofethanol in vivois unclear
but is thought to contribute at higher doses
and following chronic exposure to ethanol
(55,132,138). Chronic ethanol consumption
can result in up to a 10-fold induction in
CYP2E1 (55). The catalase system also con-
tributes to the metabolism of ethanol and
requires hydrogen peroxide. Thus, its relative
role in the metabolism ofethanol in vivo is
thought to be minimal (141).
Several studies have been conducted on
the toxicokinetic interactions between ethanol
and TCE in male rats. Exposure to ethanol in
the diet produced a 6-fold increase in the in
vitro metabolism ofTCE and an increase in
cytochrome P450 content and activity (142).
In vivo elimination was increased following
inhalation exposure to concentrations ofTCE
ranging from 500 to 8,000 ppm. Blood TCE
concentrations were decreased and the urinary
excretion ofTCA and TCOH was enhanced
at all exposure concentrations (142). These
toxicokinetic interactions between chronic
ethanol exposure and TCE in vivo are depen-
dent upon TCE exposure concentration. For
NADPII
NADP
Acetaldehyde
NAD+
.;, ALDH
NADH
Acetate
Figure 2. Biotransformation of ethanol. Metabolism
occurs primarily by hepatic ADH at low ethanol concen-
trations and following acute exposure. At higher concen-
trations and following chronic exposure to ethanol
cytochromes, P450 (CYP450), particularly CYP2E1, con-
tributes to the metabolism. Catalase plays a minor role
in ethanol metabolism. Each pathway results in the for-
mation ofacetaldehyde, which is metabolized to acetate
via ALDH.
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example, an increase in the in vivoelimination
ofTCE following chronic ethanol exposure in
male rats was found at TCE concentrations
greater than 100 ppm; exposure to either 50
or 100 ppm produced no difference in blood
TCE concentration or in the amounts ofTCA
and TCOH in the urine (143). The duration
ofexposure (142,144) and the composition
ofthe ethanol-containing diet (55,145) can
also influence the metabolic interactions and
toxicity.
Data from human males also suggest
potential influences ofchronic ethanol con-
sumption on the toxicity ofTCE. A study of
188 factory workers exposed to TCE revealed
increased hepatotoxicity in subjects who con-
sumed ethanol (146). On average, workers
were exposed for 7 hr/day for 7 years to TCE
concentrations ranging from 50 to 150 ppm.
Heavy drinkers consumed 1.5 L ofwine per
day for at least 5 years. Ofthe 51 workers
identified as heavy drinkers, 41 showed clini-
cal signs ofliver impairment. This prevalence
was statistically significantly increased com-
pared to the prevalence among workers who
were not heavy drinkers. However, because
chronic ethanol consumption causes liver
impairment, these observed effects may be
due to the presence ofethanol rather than
TCE. That is, TCE may be enhancing the
toxicity ofethanol.
Acute ethanol exposure also affects the
toxicokinetics ofTCE. Concurrent exposure
to ethanol and TCE in human males inhib-
ited the metabolism ofTCE at an exposure
concentration of50 ppm for 6 hr on 5 con-
secutive days (147). Plasma TCA and
TCOH concentrations were decreased by
one-half and one-third, respectively, com-
pared to controls. The total amount ofTCA
and TCOH excreted in the urine also
decreased 43 and 20%, respectively.
Similarly, ethanol almost completely inhib-
ited the metabolism ofa single exposure to
100 ppm TCE for 6 hr (147). Plasma TCA
levels were essentially unchanged, blood TCE
concentrations increased 2-fold, and breath
TCE concentrations increased 3-fold when
ethanol was consumed prior to and during
the TCE exposure.
Studies in rodents confirm the acute
effects ofethanol in adult men. Ethanol added
directly to microsomal incubations obtained
from rats inhibited the in vitro metabolism of
TCE (148). An acute ethanol administration
also inhibited the in vivo elimination ofTCE
when ethanol was still present in the livers of
male rats (149). Steady-state blood TCE con-
centrations were elevated in female rats
exposed to 50 or 100 ppm TCE and 0.8
mL/kg ethanol (149). These toxicokinetic
interactions are likely affected by the balance
of cofactors necessary for TCE and ethanol
oxidation, and inhibition ofTCE following
acute exposure to ethanol is likely due to a
shift in the NADH:NAD+ ratio (150-152).
Acutely, ethanol may also interact with
the metabolites ofTCE, specifically CH and
TCOH, since ethanol and CH are both
metabolized by ADH and have similar phar-
macological properties (75). For example,
male subjects who were administered ethanol
following the administration ofCH had sig-
nificantly higher plasma TCOH levels com-
pared to CH alone, and levels were prolonged
in the ethanol-exposed subjects (153). A
decrease in plasmaTCAwas also found in the
ethanol-exposed subjects, as well as an
increase in urinary TCA and a decrease in
urinary TCOH production. The authors sug-
gest the ethanol-induced increase in plasma
TCOH concentration is due to an increase in
the metabolism of CH to TCOH and a
decrease in the glucuronidation ofTCOH.
Although experimental studies in humans
exposed to both TCE and ethanol are lim-
ited, pharmacokinetic modeling has provided
insight regarding the effects of potential
interactions. Simulation studies using a
PBPK model for TCE and ethanol were con-
ducted to examine the interactions between
acute and chronic ethanol and TCE (154).
Based on previous studies conducted in male
rats, the metabolism ofTCE following acute
exposure to ethanol was assumed to be com-
petitively inhibited and was described using
the Michaelis-Menten expression for com-
petitive inhibition. CYP2E1 induction fol-
lowing chronic ethanol exposure was
simulated by an increase in the Vm,,, for the
metabolism ofTCE.
Moderate doses ofethanol consumed 15
min prior to a 6-hr exposure to 50 ppm TCE
resulted in increases in blood TCE concentra-
tions and corresponding decreases in the rate
ofexcretion ofurinary metabolites (152). At
the highest ethanol dose (20 mmol/kg), blood
TCE concentrations increased 70% and the
urinary excretion rate of total urinary
metabolites decreased 40%. This dose of
ethanol corresponds to approximately 6-9
standard drinks in a 70-kg man and 5-8
drinks in a 60-kg female.
The induction ofCYP2E1, simulated by
a 5-fold increase in the Vmax, had a slight
effect on TCE metabolism (154). Blood
TCE concentrations were decreased 10% and
the excretions of urinary TCA and TCOH
was increased by less than 10%. Simulations
at TCE concentrations higher than 500 ppm
showed a much greater effect on the decrease
in blood TCE and the increase in urinary
TCAand TCOH formation.
The minimal effect ofCYP2E1 induction
on the metabolism oflow concentrations of
TCE is due, at least in part, to the intrinsic
clearance ofTCE. When concentrations of
TCE are low, the metabolism is blood-flow
limited and the effect ofCYP2E1 induction is
minimal. At higher concentrations when
metabolism is saturated, CYP2E1 induction
results in an increase in the capacity to metab-
olize TCE, which increases the in vivo elimi-
nation and formation oftoxic metabolites.
Predictions based on in vitro studies of
TCE metabolism (40) and PBPK model sim-
ulations in human males (155) suggest the
metabolism ofTCE in humans at occupation-
ally relevant concentrations (50 ppm) is not
saturated. Accordingly, a significant increase
in the formation oftoxic metabolites formed
from the oxidative pathway would not be
expected. However, a 10% increase in the for-
mation oftoxic metabolites, as predicted by
the PBPK model, might be enough to
enhance the toxicity ofTCE, particularly over
long-term TCE exposure. The simulations
accounted for a 5-fold induction in CYP2E1,
and chronic ethanol consumption can result
in up to a 10-fold induction of CYP2E1
(132). Moreover, up to a 20-fold variation in
CYP2E1 activity can occur (138).
The extent of TCE metabolism in
humans was found to be correlated with
cytochrome 450 activity and content (40).
Although Lipscomb et al. found that
CYP2E1 activity varied less than 10-fold,
these studies were conducted on a limited
number ofsubjects and cannot necessarily be
generalized to all populations. For example,
subjects who consumed alcohol were not
included in this study. Furthermore, the
short-term exposure limit for TCE is 200
ppm and was set to protect against the anes-
thetic effects ofTCE (29). The minimal risk
level (MRL), which is the estimated daily
human exposure to a hazardous substance
that is likely to be without appreciable risk of
adverse noncancer health effects over a speci-
fied duration oftime and is set byATSDR, is
well below 200 ppm for TCE (12). The
MRLs for acute and intermediate inhalation
exposure to TCE are 2 and 0.1 ppm, respec-
tively. Thus, when CYP2E1 is induced, an
increase in the formation oftoxic metabolites
will likely occur at TCE concentrations at or
near 200 ppm. The anesthetic effects ofacute
ethanol and TCE will be enhanced when
exposure to both occurs at this concentration.
Another possible interaction that has not
been studied is the effect ofethanol-induced
glutathione depletion on the metabolism of
TCE to DCVG. Ethanol decreases hepatic
mitochondrial glutathione levels (156),
which in turn impairs mitochondrial function
(157). The formation ofDCVG from glu-
tathione conjugation has been implicated as a
possible mechanism for the nephrotoxicity
and nephrocarcinogencity of TCE (15).
Thus, ethanol exposure has the potential to
affect susceptibility to TCE via interaction
with this pathway.
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Most studies on the interaction between
TCE and ethanol were conducted in male
rats, as well as a limited number ofstudies in
human males. Caution should be used when
extrapolating these findings to females, partic-
ularly since significant sex-dependent differ-
ences in the affinity to metabolize TCE were
observed in humans (40). As discussed above,
sex-dependent difference in the toxicity of
TCE and TCA also exists. In addition, there
are sex-dependent differences in the pharma-
cokinetics and toxicity ofethanol; women are
more susceptible to the adverse effects of
ethanol (158-163).
While studies have not been conducted
on the interactions between ethanol andTCE
in pregnancy, studies in rats showed an eleva-
tion in cardiac malformation in rat pups
exposed to DCA, TCA, or TCE in utero
(18,100,164). An increase in cardiac anom-
alies was found in children born to mothers
exposed to drinking water containing, among
other contaminants, TCE and DCA (17,18).
Exposure to ethanol in utero also results in
cardiac malformations in humans (165).
The induction ofCYP2E1 by ethanol in
the fetus and developing infant may also
increase the likelihood of developmental
effects ofTCE and/or ethanol. Recent studies
found elevated CYP2E1 levels and an increase
in activity in rat pups exposed to ethanol in
utero (166) as well as pups exposed translac-
tationally (167). Ethanol has been measured
in the breast milk oflactating women (168).
Recent studies in women with a history of
heavy drinking found an increase in the
expression ofCYP2E1 in third-term placentas
(169). A 2-fold induction in CYP2E1 levels
was found in fetal hepatocyte cultures treated
with ethanol (170). The estimated incidence
offetal alcohol syndrome (FAS), a syndrome
of anomalies resulting from exposure to
ethanol in utero, is 9.7 per 10,000 live births;
among heavy drinkers, 4.3% ofchildren are
born with FAS (171). Therefore, the possibil-
ity ofinduction of CYP2E1 in the placenta
and/or human fetus exists and this may lead
to a subsequent increase in susceptibility to
the developmental effects ofTCE.
The data presented thus far illustrate that
interactions between ethanol and TCE occur
in both rodents and humans followirng acute
and chronic ethanol exposure. There are lim-
ited data in rodents and humans, suggesting
that chronic ethanol consumption leads to
greater hepatotoxicity ofTCE and that acute
ethanol consumption increases the CNS
effects ofTCE. Alcoholics are often warned
about a potential increase in the adverse
health effects ofmany drugs. For example,
the U.S. Food and Drug Administration will
be requiring an alcohol warning on all over-
the-counter medications containing aceta-
minophen because induction of CYP2E1
causes an increase in the hepatotoxicity of
acetaminophen (172). Given that there are
over 80 exogenous chemicals metabolized by
CYP2E1, physicians should probably warn
alcoholics ofthe potential increase in adverse
health effects ofenvironmental contaminants.
Prior and concurrent exposures. Suscepti-
bility may be altered simply by increasing the
body burden ofa given environmental agent
or its metabolites. In some cases a threshold
may be reached. Previous exposures may
enhance susceptibility by sensitizing the indi-
vidual to the compound, either directly or by
cross-sensitization. Prior exposure to various
chemicals may also interfere with metabolism
through inhibition or induction, which in
turn can alter susceptibility.
For example, Lipscomb et al. (40) studied
the effect ofTCE on specific cytochrome
P450 isozyme activities using mouse, rat, and
human hepatic microsomes. TCE was a com-
petitive inhibitor ofCYP2E1 activity, and a
noncompetitive inhibitor of CYP3A and
CYP2B. Addition ofTCE at 1,000 ppm
inhibited CYP2E1 activity in all three species,
and CYP3A activity in mice and rats. Prior
exposure to TCE had no effect on CYP2A
activity but did increase CYPlA1/1A2 activ-
ity. In addition, animal studies show DCA
inhibits its own metabolism (173). Thus,
DCA levels may accumulate with prior or
prolonged exposure.
Nakajima et al. (52) compared the rela-
tive contribution ofthe P450 isozymes in the
metabolism ofTCE in rats. Hepatic micro-
somes were obtained from control rats, and
rats previously exposed to phenobarbital,
ethanol, or 3-methylcholanthrene were used.
CYP2E1, CYP2E11/6, CYPIIB1/2, and
CYPIA1/2 were involved in conversion of
TCE to CH, with some variation in isozyme
levels at different TCE concentrations. At low
TCE levels, adding anti-CYP2E1 antibodies
inhibited TCE metabolism in ethanol-treated
rats more greatly than in controls. In contrast,
CH formation was inhibited by anti-
CYP2C11/6 in control and PB-treated rats at
high but not low TCE concentrations, with a
lower net inhibition than from using anti-
CYP4502E1. Anti-CYP3B1/2 and anti-
CYPA1/2 inhibited CH formation from
phenobarbital and 3-methylcholantherene-
treated rats, particularly at high TCE concen-
trations. CYP2B1 contributed more to TCE
oxidation than CYPIC1/6, but the reverse
was seen for toluene metabolism. In conclu-
sion, CYP2E1, 1A1/2, 2C11/6, and 2B1/2
are all involved in metabolism ofbenzene,
toluene, and TCE, indicating broad and
overlapping substrate specificity of these
volatile compounds.
Prior exposure to solvents such as toluene
can induce CYP450s, which in turn can
affect TCE metabolism (174). Both sex and
age influence CYP450 induction after toluene
exposure; in general, induction is greater in
younger animals and higher in males (55).
Neonatal exposure ofrats to toluene greatly
affected liver microsomal CYP450 activity at
birth, whereas minimal effects were seen in
rats exposed at 3 weeks ofage (174).
Alteredhealth state. An additional popula-
tion that deserves consideration in the evalua-
tion ofsusceptibility to environmental toxins
is persons whose health state is altered. This is
important because ofthe effects ofcertain dis-
eases on the ability ofthe body to process
chemicals. For example, the ability to renally
excrete chemicals can be diminished in people
with kidney impairment, leading to an
increase in toxicity. The phenomenon is read-
ily apparent with antibiotics. The majority of
antibiotics and their metabolites, such as van-
comycin and aminoglycosides, are eliminated
by the kidneys. In patients with renal insuffi-
ciency, dosages ofthese drugs are adjusted
accordingly to avoid overt excessive toxicity
(175). Liver disease also affects the ability to
metabolize and eliminate chemicals. For
example, rifampin and isoniazid have pro-
longed half-lives in people with cirrhosis
(175). These same principles apply following
exposure to environmental chemicals and may
contribute to differences insusceptibility.
As previously discussed, uncontrolled
diabetes results in an induction ofCYP2E1,
which can lead to an increase in the forma-
tion oftoxic metabolites. Diabetics are also at
greater risk for liver cancer. Recent studies in
the Swedish population show a 4-fold
increase in the risk for development ofpri-
mary liver cancer in patients with diabetes
mellitus versus the general population (176).
Similar results were reported in studies from
Italy, Denmark, and Los Angeles (177-179).
Diabetics may be a population susceptible to
the potential hepatotoxic effects ofTCE.
The effect ofDCA on blood glucose and
serum insulin levels is ofadditional concern
for diabetics. An increase in serum insulin
levels in mice exposed to < 0.5 mg/L DCA in
the drinking water was found (22). This has
not been found in humans. But DCA reduces
hyperglycemia in insulin and non-
insulin-dependent diabetics by stimulating
blood glucose oxidation in peripheral tissues,
stimulating glycogensis from glucose in
adipocytes, and depleting hepatic and muscle
glycogen levels (180). These effects have been
observed in both animals and humans. DCA
also decreases hyperglycemia through stimu-
lation ofpyruvate dehydrogenase (PDH)
(181). DCA inhibits pyruvate dehydrogenase
kinase, which maintains PDH in its unphos-
phorylated, catalytically active state (181).
PDH controls the rate ofglucose and pyru-
vate oxidation, and the net effect is a decrease
in blood glucose levels, as well as a dramatic
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and prolonged decrease in lactate and aniline
levels (181).
Several studies have been conducted in
humans to evaluate the potential use ofDCA
in the treatment ofhyperglycemia in diabetics,
as well as in the treatment oflactic acidosis,
hyperlipidemia, ischemic heart disease, and
heart failure. The treatment regimen used in
lactic acidosis consists ofa30-min intravenous
infusion of 50 mg/kg followed by a second
infusion ofthe same dose 2 hr after initiation
ofthe first dose (182). This dosing regimen,
which results in a rapid decrease in plasma lac-
tate and glucose concentrations, produced
maximum plasma DCAconcentrations of144
± 92 mg/L and 180 ± 92 mg/L following the
first and second infusion, respectively, in adult
patients with lactic acidosis (182). These lev-
els are much greater than those measured in
healthy human subjects exposed to occupa-
tionally relevant concentrations of TCE
(183). In this study, subjects were exposed to
100 ppm TCE for 4 hr, and TCE and
metabolite levels were measured in blood and
urine. DCA was detected intermittently, with
as high as 0.014 mg/L measured in one sub-
ject. It is unlikelythat exposure to occupation-
ally relevant TCE concentrations will produce
blood DCA levels that would result in a
decrease in hyperglycemia in diabetics.
However, DCA administration in humans
has been limited to 2 weeks and chronic
administration has not been examined.
Because DCA inhibits its own metabolism,
prolonged and/or repeated administration may
lead to sustained concentrations that may
result in an irreversible inactivation of the
PDH (180). Thus, an increase in susceptibility.
ofdiabetics to the effects ofthe TCE metabo-
lite DCA on blood glucose levels cannot be
ruled out until furtherstudies areconducted.
Discussion
As discussed earlier, for most environmental
chemicals data on susceptible subgroups are
rarely available. The use oflinear low-dose
extrapolation in cancer assessments has been
assumed to be conservative enough not to
underestimate risk for susceptible members of
the population (9). Noncancer assessments
acknowledge response variability within the
population by an uncertainty factor (current
practice uses a default value of 10)(183).
However, the scientific basis for default
assumptions remains questionable, particu-
larly in light of the myriad factors that can
potentially alter toxicity. A person's response
to environmental hazards is affected byphysi-
ological variables including exposure route
(respiratory rates, dermal penetration/irrita-
tion, etc.), pharmacokinetics (distribution,
absorption, metabolism, excretion), and phar-
macodynamics (receptor density, organ speci-
ficity). These variables are in turn affected by
constitutive factors (genetics, gender, age,
ethnicity) and acquired factors (disease state,
diet, exercise, stress, effects of previous or
concurrent exposures).
While a small number ofhuman carcino-
gens show variable effects in outcome follow-
ing exposure, our understanding of the
inherent variability in subpopulations is lim-
ited, and epidemiological and laboratory
studies on this subject are in their infancy
(184). While heredity clearly has an impact
on exposure-driven cancer, not enough is
known about the correlation to harness it in
improving public health (184).
Ethnic groups vary in their distributions
ofgenotypes, and extrapolation ofhealth out-
comes between the different groups is very
difficult (51). In the United States, overall
disease rates are higher in African-Americans
than in Caucasians. Molecular epidemiology
suggests different patterns ofexposure and/or
internal handling ofexogenous or endoge-
nous carcinogens along racial or ethnic lines,
and different patterns ofsusceptibility mark-
ers are seen (184).
Despite the observational correlations,
biologically plausible mechanisms to link
specific genotypes to specific outcomes are
still lacking for most diseases; for example,
many RFLP polymorphisms in Class I genes
are the result ofmutations in introns or other
silent areas ofthe human genome (51), and
molecular methods are still oflimited utility
in predicting susceptibility at this time.
Furthermore, it is difficult to disentangle out-
comes that are the result ofgenetic traits, par-
ticularly when associated with ethnicity, from
socioeconomic and behavioral factors that
also may affect environmental exposure
orsusceptibility.
In some cases, risk reduction can be
achieved by going beyond risk regulation and
taking a public health approach promoting
healthy activities in conjunction with an
increased understanding of the biological
mechanisms of toxicity, which may allow
development ofmore effective interventions.
Examples ofsuccessful interventions include
controlling smoking and radon exposure,
smoking and asbestos exposure, and CYP450
induction and alcohol/smoking.
While environmental prevention strate-
gies focus on reducing exposure in the work-
place and environment, intervention
strategies are geared toward the population as
a whole and do not inherently address
genetic differences among individuals (185).
Some contend that current environmental
risk assessment methods do not provide suffi-
cient protection, as they assume similar bio-
logical responses from all individuals for a
specified dose of a toxic agent (185). This
results in regulatory and health policies
aimed at protecting the "average American,"
ignoring a sizable, more vulnerable fraction
ofthe population (51,184). Conversely, oth-
ers contend that the default safety factors
used in human risk assessment are overpro-
tective of the population, resulting in high
regulatory costs at the expense ofindustry.
The new U.S. EPA cancer guidelines pro-
posed in 1996 discuss the importance of
incorporating information on susceptibility.
The NRC and the Presidential Commission
on Risk Assessment and Risk Management
have recommended that the U.S. EPA
develop explicit methods for assessing suscep-
tibility, using molecular epidemiology and
other population-based information to deter-
mine the magnitude ofvariability (5).
In order to better protect vulnerable
groups and the population as a whole, accu-
rate data on susceptible groups are needed
and should be directly incorporated into risk
assessment processes to allow development of
better health-based policies (3,5). More
mechanistic information is needed to allow
better understanding ofhow different factors
influence toxicity, and how these vary accord-
ing to genetic profile, behavior, and age. For
example, molecular biomarkers ofexposure
and effect are increasingly being used in epi-
demiological analyses to improve the resolu-
tion ofrisk factors and to better understand
the basic underlying mechanisms responsible
for disease (185). Biomarkers can serve as an
early indicator ofexposure or susceptibility
before clinical signs manifest, allowing early
interventions. The distribution ofbiomarkers
in a population can potentially be used to
improve the quantitative estimates of risk
from agiven exposure, and to identifysuscep-
tible groups or even individuals who may be
at risk (51,185).
A more comprehensive documentation
and understanding ofsex- and species-depen-
dent differences in metabolism is essential for
extrapolating animal data to humans, for
refining risk assessment models and methods,
and for better determining safe exposure levels
forhumans.
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